Management Team

Stefan Aigner, M.D., CFA

More than 30 years of broad healthcare industry experience
Co-founder and CEO of Inspirion Delivery Technologies and Inspirion Delivery Sciences. Garnered approval of two abuse-deterrent products and raised funding that exceeded $50 MM while negotiating a significant non-dilutive partnership with Daiichi Sankyo.
Former EVP of corporate development at Alpharma (acquired by King Pharmaceuticals in 2008 for $1.6 billion).
Co-Founder and EVP of business development and scientific affairs at Reliant Pharmaceuticals. Built a fully integrated pharmaceutical company with 1,400 employees (acquired by GlaxoSmithKline in 2007 for $1.7 billion).
Healthcare management consultant for the Wilkerson Group
Board of publicly traded Cipher Pharmaceuticals.

More than 30 years of pharmaceutical industry experience in drug delivery systems and product development technology.
Spent 20 years with Ethypharm S.A. of France of which 12 years as CEO of Ethypharm North America.
Headed company strategy, established and managed alliances and partnerships with both specialty pharma and generic companies in the US, Canada, and Latin America, primarily in pain management and treatment of substance abuse disorders.
Spent 10 years in Europe with Glatt AG & Glatt GmbH, world leaders in pharmaceutical products processing.

Seasoned operational finance professional with 22 years of experience in pharma, medical devices, and technology.
Has supported IPO processes, equity capital raises, and secured debt facility and revolver.
Provided key cross-functional support across the human resources, information technology, and commercial operations functions to create successful processes in both startup and large global companies to support a number of commercial launches.

More than 20 years of experience in product development, precommercial strategy and planning, pre- and post-approval regulatory and compliance, and go to market execution in specialty pharma.
Head of medical affairs at Inspirion Delivery Sciences and Xanodyne Pharmaceuticals, overseeing labeling, publication planning, promotional review, pharmacovigilance, medical information, and grant making.
Strategic consultant for sponsors developing abuse-deterrent technologies, preparing for FDA meetings and advisory committees, and launching novel products.
Board of MDDUS at Supernus Pharmaceuticals.

More than two decades of experience within a pharmaceutical environment.
Lead the implementation of marketing tactics with multi-million-dollar budgets.
Comprehensive experience leading marketing and communication efforts for commercial operations across multiple functional areas.